Current Research in Translational Medicine最新文献

{"title":"Corrigendum to “AI-assisted statistical review of 100 oncology research articles: compliance with SAMPL guidelines” [Current Research in Translational Medicine 73 (2025) 103544]","authors":"Michal Ordak","doi":"10.1016/j.retram.2025.103558","DOIUrl":"10.1016/j.retram.2025.103558","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103558"},"PeriodicalIF":3.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","authors":"Turkan Aliyeva ,&nbsp;Haroon Alamy ,&nbsp;Feras Ahmad Ibrahim Ahmad ,&nbsp;Julia Natche ,&nbsp;Hafiz Shah ,&nbsp;Vrushali Shelar ,&nbsp;Huu Than Huynh ,&nbsp;Imane El Amri","doi":"10.1016/j.retram.2025.103559","DOIUrl":"10.1016/j.retram.2025.103559","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities. Anti-CD38 monoclonal antibodies, particularly daratumumab, have emerged as promising additions to frontline regimens. However, the long-term outcomes of these therapies are still uncertain. This systematic review and meta-analysis aimed to compare the survival outcome of anti-CD38 antibodies in TIE-NDMM patients.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) published up to April 2025 comparing anti-CD38 mAbs based regimens versus standard therapy in transplant-ineligible NDMM patients. A random-effects model was used to calculate pooled hazard ratios (HRs) with 95 % confidence intervals (CIs).</div></div><div><h3>Results</h3><div>A total of six RCTs with 2,625 patients were included in the analysis. Of these, 1,390 (52.9 %) patients received anti-CD38-based regimens. The follow-up duration varied from 41.2 to 86.7 months across the studies. Compared to standard therapy, anti-CD38-based regimens significantly improved both overall survival (OS) (HR 0.70; 95 % CI 0.58–0.84; p=0.0002; I² = 46 %) and progression-free survival (PFS) (HR 0.57; 95 % CI 0.51–0.65; p &lt; 0.00001; I² = 15 %). The pooled results demonstrated that non-frail patients had a longer PFS than frail patients (HR = 0.46; 95 % CI, 0.34–0.63 and HR = 0.55; 95 % CI, 0.45–0.67, respectively), although the difference between the subgroups was not statistically significant (p = 0.36).</div></div><div><h3>Conclusion</h3><div>In transplant-ineligible NDMM patients, the addition of anti-CD38 monoclonal antibodies to standard regimens significantly improves clinical outcomes. These findings support the integration of anti-CD38 therapy into first-line treatment for this vulnerable patient population<strong>.</strong></div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103559"},"PeriodicalIF":3.0,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of published clinical studies using cell-derived extracellular vesicles: A focus on efficacy in COVID-19 and wound healing","authors":"An Duong ,&nbsp;Philippe Giguère ,&nbsp;Risa Shorr ,&nbsp;David S. Allan","doi":"10.1016/j.retram.2025.103557","DOIUrl":"10.1016/j.retram.2025.103557","url":null,"abstract":"<div><h3>Background</h3><div>Extracellular vesicles (EVs) are nano-sized membrane-bound particles released from cells and offer promise in cell-based regenerative therapy. Preclinical research has propelled the launch of clinical trials with results from initial studies recently published. A systematic review is needed to evaluate trial designs, outcomes, product characterization and safety profiles to identify barriers and inform future research directions.</div></div><div><h3>Methods</h3><div>A systematic search of the literature was conducted (1946 to September 19, 2024) to identify clinical studies using cell-derived EVs. We extracted aspects of study design, diseases being treated, characteristics of trial subjects, isolation methods and characterization of EVs, details of product administration, main conclusions, and aspects of potential study bias.</div></div><div><h3>Results</h3><div>Twenty-five published clinical trials were included for analysis. COVID-19 and associated acute respiratory distress syndrome (ARDS) were studied most frequently (<em>n</em> = 8, 32 %). Wound healing was the second largest disease category (<em>n</em> = 5, 20 %). Seven studies (28 %) were controlled trials. Mesenchymal stromal cells (MSCs) were the most common source of EVs (20 studies, 80 %), with 494 patients receiving MSC-EVs for various indications. Most trials (68 %, <em>n</em> = 17) used ultracentrifugation as the primary method for EV isolation. An individual patient data meta-analysis of controlled COVID-19/ARDS trials investigating MSC-EVs (<em>n</em> = 3; 5 intervention groups) revealed an odds ratio (OR) for mortality of 0.46 (95 % CI 0.26 - 0.81; <em>p</em> = 0.0073). The benefits of EVs to improve wound healing are less clear with no controlled studies of MSC-EVs and no clear benefit reported in 2 controlled studies of other cell-based EVs. Although administration of EVs was generally well tolerated, safety conclusions remain preliminary given that only one serious adverse event was explicitly reported, and adverse event reporting was often incomplete.</div></div><div><h3>Conclusions</h3><div>Clinical trials of cell-derived EVs demonstrate marked heterogeneity but potential promise using MSC-EVs to treat COVID-19/ARDS, although efficacy in wound healing is less clear. More controlled studies are needed to optimize and confirm these initial results and to establish a more definitive understanding of the safety profile of EV therapy.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103557"},"PeriodicalIF":3.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene","authors":"Giovanni Iaquinta ,&nbsp;Alessandro Laganà ,&nbsp;Caterina Tatarelli ,&nbsp;Arianna Di Napoli ,&nbsp;Serena Pasquali ,&nbsp;Agostino Tafuri ,&nbsp;Massimo Breccia ,&nbsp;Paola Grammatico","doi":"10.1016/j.retram.2025.103556","DOIUrl":"10.1016/j.retram.2025.103556","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103556"},"PeriodicalIF":3.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimerism in blood after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: Results from a cohort study","authors":"Farah Khemir ,&nbsp;Anaïs R. Briant ,&nbsp;Anne-Claire Gac ,&nbsp;Jean-Baptiste Mear ,&nbsp;Hyacinthe Johnson-Ansah ,&nbsp;Gautier Petit-Bultez ,&nbsp;Jean-Jacques Parienti ,&nbsp;Gandhi Damaj ,&nbsp;Oumedaly Reman ,&nbsp;Erwann Quelvennec ,&nbsp;Sylvain Chantepie","doi":"10.1016/j.retram.2025.103550","DOIUrl":"10.1016/j.retram.2025.103550","url":null,"abstract":"<div><h3>Background</h3><div>Allogeneic hematopoietic stem cell transplantation (HSCT) is still a curative option in acute myeloid leukemia treatment (AML) owing to a long-lasting graft-versus-leukemia effect. Relapse remains its major cause of failure. Preemptive strategies based on biological markers for impending relapse have been proven with better outcomes than salvage treatment.</div></div><div><h3>Methods and Findings</h3><div>We investigated chimerism-based preemptive immunomodulation in 90 HSCT patients with AML. Primary endpoint was relapse risk assessment by real time quantitative PCR (q-PCR) chimerism monitoring in blood. Post-HSCT unfractionated peripheral blood (PB) and bone marrow (BM) samples were timely collected for q-PCR assays. Increasing mixed chimerism (IMC) was defined as a significant increase of percentage of recipient-derived cells between two consecutive samples. Patients were stratified into three groups: no IMC, one IMC with no further IMC and two consecutive IMC. Preemptive immunomodulation (fast tapering of immunosuppressive treatment and/or donor lymphocyte infusion) was triggered by the first documented IMC, and 2 consecutive IMC triggered minimal measurable disease assessment. PB assays compared favorably with BM in our cohort. The risk of relapse was higher in patients with two consecutive IMC (SHR 2·9, 95 % CI: 1·4 - 6·0, <em>p</em> = 0·005) and overall survival was shortened (HR 2·2, 95 % CI: 1·01 - 4·7, <em>p</em> = 0·048).</div></div><div><h3>Conclusion</h3><div>Serial monitoring of q-PCR chimerism in PB may be a relevant tool for impending relapse detection in post-HSCT acute myeloid leukemia.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103550"},"PeriodicalIF":3.0,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury","authors":"Nicolò Peccatori ,&nbsp;Gianluigi Ardissino ,&nbsp;Simone Cesaro ,&nbsp;Romano Danesi ,&nbsp;Stefania Gaspari ,&nbsp;Cristina Meazza ,&nbsp;Rossella Mura ,&nbsp;Carmelo Rizzari","doi":"10.1016/j.retram.2025.103551","DOIUrl":"10.1016/j.retram.2025.103551","url":null,"abstract":"<div><h3>Background</h3><div>High-dose methotrexate (HD-MTX) is used to treat various malignancies in adults and children. However, HD-MTX can lead to severe toxicity, which can require the use of glucarpidase, a recombinant enzyme that rapidly reduces MTX concentrations. Current guidelines, approximated from both adult and pediatric studies and established prescribing indications, do not provide detailed recommendations tailored to children to guide glucarpidase use in clinical practice.</div></div><div><h3>Methods</h3><div>The current study used modified Delphi methodology to develop expert consensus recommendations for the safe administration of HD-MTX, and management of delayed MTX elimination (DME) and/or HD-MTX–induced acute kidney injury (AKI) in children with cancer. Consensus statements were developed by a multidisciplinary Scientific Board of eight Italian physicians, then circulated to an expert panel of 20 pediatric hemato-oncologists for voting. Expert panel members rated their level of agreement using a 5-point Likert scale; consensus was reached if ≥66.6 % of respondents indicated that they “agreed” or “strongly agreed” with each statement.</div></div><div><h3>Results</h3><div>Of the 46 statements, 40 achieved consensus. Clinicians agreed that harmonized glucarpidase treatment guidelines are needed. Careful risk assessment performed by a multidisciplinary team should be established to ensure correct management of pediatric patients on relevant factors such as concomitant medications, monitoring of plasma MTX levels for DME, collection and processing of blood samples, monitoring of renal function for AKI prevention or management, and prompt availability of glucarpidase.</div></div><div><h3>Conclusions</h3><div>These expert consensus recommendations will help pediatric hemato-oncologists to better deal with the various aspects associated with managing HD-MTX in general and with DME or AKI in particular.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103551"},"PeriodicalIF":3.0,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained remission in relapsed/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk","authors":"Massimiliano Marinoni ,&nbsp;Lucrezia De Marchi ,&nbsp;Federico Meconi ,&nbsp;Alice Di Rocco ,&nbsp;Luca Franceschini ,&nbsp;Marco Iannetta ,&nbsp;Manuela Rizzo ,&nbsp;Massimiliano Postorino ,&nbsp;Adriano Venditti ,&nbsp;Fabiana Esposito","doi":"10.1016/j.retram.2025.103549","DOIUrl":"10.1016/j.retram.2025.103549","url":null,"abstract":"<div><h3>Background</h3><div>The therapeutic landscape for relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) is expanding, with bispecific antibodies emerging as key treatment strategies. These drugs have demonstrated high efficacy in this setting of patient, but leading to prolonged immunosuppression, exposing patients to a high risk of infections. We describe a R/R DLBCL patient achieving complete remission (CR) with glofitamab, although discontinued due to JC virus reactivation. Nineteen months post-treatment, the patient remains in CR, with declining viral copies and no evidence of neurological complications. The patient also has a history of chronic myeloid leukemia (CML), currently in treatment free remission (TFR). This is an example of durable DLBCL remission despite abbreviated glofitamab therapy, while highlighting challenges in balancing immunotherapy efficacy with opportunistic infection risks.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103549"},"PeriodicalIF":3.0,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IDH1 mutation in acute lymphoblastic leukemia—A rare but significant finding","authors":"Elisa Buzzatti ,&nbsp;Luca Guarnera ,&nbsp;Giovangiacinto Paterno ,&nbsp;Carla Mazzone ,&nbsp;Valerio Santoro ,&nbsp;Tiziana Ottone ,&nbsp;Marco Zomparelli ,&nbsp;Kleda Zaganjori ,&nbsp;Valeria Guzman ,&nbsp;Cristina Mauro ,&nbsp;Maria Teresa Voso ,&nbsp;Adriano Venditti ,&nbsp;Maria Ilaria Del Principe","doi":"10.1016/j.retram.2025.103548","DOIUrl":"10.1016/j.retram.2025.103548","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103548"},"PeriodicalIF":3.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA molecules: Another challenge for CAR T cell therapy","authors":"Ikram Salih ,&nbsp;Meryem Fakhkhari ,&nbsp;Hicham Berrougui ,&nbsp;Abdelouahed Khalil ,&nbsp;Karim Benabdellah ,&nbsp;Erden Atilla ,&nbsp;Khalid Sadki","doi":"10.1016/j.retram.2025.103547","DOIUrl":"10.1016/j.retram.2025.103547","url":null,"abstract":"<div><div>CAR-T cell therapy marks a groundbreaking advancement in the treatment of hematological malignancies, demonstrating significant potential to induce durable remissions. However, several limitations hinder its effectiveness, including antigen loss, immune evasion, and hostile tumor microenvironment. The interplay between CAR-T cell therapy and HLA molecules, particularly HLA-DR and HLA-G, emphasises critical challenges to achieving sustained therapeutic success. Monocytes with low or negative HLA-DR expression and high HLA-G presence contribute to immune evasion and reduced CAR-T cell effectiveness. Additionally, genetic variations in HLA influence susceptibility to hematological malignancies and disease progression. Therapeutic strategies to regulate HLA expression and function are crucial to overcome these obstacles. Approaches such as blocking HLA-G, enhancing HLA-DR expression, and optimising HLA profiles in patients by gene editing can improve outcomes of CAR-T cell therapy. Continued research on HLA-mediated immune modulation will improve these strategies and advance CAR-T cell therapy.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103547"},"PeriodicalIF":3.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital pathology and artificial intelligence in the era of modern slides: A state of the art","authors":"Sawsan Ismail ,&nbsp;Firas Shammas ,&nbsp;Yamam Makhlof ,&nbsp;Hala Mohammad Al Ali ,&nbsp;Zuheir Alshehabi ,&nbsp;Kanaan Al-Tameemi ,&nbsp;Tamim Alsuliman","doi":"10.1016/j.retram.2025.103546","DOIUrl":"10.1016/j.retram.2025.103546","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103546"},"PeriodicalIF":3.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}